LONDON (Reuters) - An experimental cancer drug developed by Britain's GlaxoSmithKline may add vital months to the lives of melanoma patients whose disease has spread to their brains, according to data from an early-stage trial published on Friday. Results of Phase I trial published in The Lancet medical journal showed substantial shrinking of tumors in patients treated with the drug, dabrafenib, and showed promise against secondary melanoma tumors, or metastases, in the brain. ... Original Source
No comments:
Post a Comment